"A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

TPS2616Background: Spartalizumab is an immunoglobulin G4 humanized monoclonal antibody that binds with subnanomolar affinity to PD-1. LAG525 is an immunoglobulin G4 humanized monoclonal antibody th... Click to show full abstract

Keywords: combination spartalizumab; study combination; lag525; phase open; open label; label study

Journal Title: Journal of Clinical Oncology
Year Published: 2018

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
1

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended